Novo Nordisk (NOVO.B) Stock: The $2 Billion Weight Loss Drug That Just Proved Its Worth
TLDR UBT251 produced mean weight loss of up to 19.7% after 24 weeks in a mid-stage Chinese trial The drug targets three hormones — GLP-1, GIP, and glucagon — earning it the “triple G” label Side effects were mild to moderate and decreased over time Results arrive one day after CagriSema failed to beat Eli Lilly’s Zepbound in a head-to-head trial Novo holds global rights to UBT251 under a deal worth up to $2 billion signed in March 2025 Novo Nordisk and United Laboratories International reported Tuesday that their experimental obesity drug UBT251 achieved mean weight loss of up to 19.7% after 24 weeks in a mid-stage clinical trial in China. Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China. Learn more in the press release here: https://t.co/pA8XmwtRAN pic.twitter.com/3tWDHcF3aD — Novo Nordisk (@novonordisk) February 24, 2026 The placebo group lost just 2.0% over the same period. Patients started from a baseline mea...